Table 1.

HCV Drugs Currently Under Advanced Study

Drug	Manufacturer	Mechanism of Action
Albumin interferon	Human Genome Sciences/Novartis	Immunotherapeutic: IFN with a 2–4 week plasma half-life
Taribavirin	Valeant	Immunotherapeutic: RBV analogue (prodrug) to decrease RBV-induced anemia
BILN 2061	Boehringer Ingelheim	Protease inhibitor to HCV NS3
Boceprevir/SCH 503034	Schering-Plough	Protease inhibitor to HCV NS3
Telaprevir/VX-950	Vertex	Protease inhibitor to HCV NS3
R7128	Pharmasset/Roche	NS5b HCV polymerase inhibitor: nucleoside analogue
Valopicitabine/NM-283	Idenix/Novartis	NS5b HCV polymerase inhibitor: nucleoside analogue
R1626	Hoffman-La Roche	NS5b HCV polymerase inhibitor: nucleoside analogue
HCV-796	Viropharma/Wyeth	NS5b HCV polymerase inhibitor: nonnucleoside allosteric inhibitor
DEBIO-025	Debiopharm	Cyclophilin analogue interferes with HCV polymerase
Nitazoxanide	Romark	Unknown mechanism of action

HCV

hepatitis C virus

IFN

interferon

RBV

ribavirin